|
private:pangaeabiotech-2
|
1301518
|
May 30th, 2019 12:00AM
|
Pangaea Oncology
|
631
|
25.00
|
Open
|
Hospital & Health Care
|
May 30th, 2019 07:52PM
|
May 30th, 2019 07:52PM
|
Founded in Barcelona in 2007, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.
The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
The synergy between these areas forms the foundation of Pangaea's future growth strategy.
Pangaea's Chief Scientific Officer is international expert in translational cancer research Dr Rafael Rosell, and our Pathology Unit is led by renowned expert pathologist Dr Santiago Ramon y Cajal. CEO Javier Rivela has over 12 years experience in investment banking.
Pangaea was the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (nº750 / LE15156 Annex 7). The laboratory is also accredited for analysis of EGFR mutations (exon 19, 20 (T790M) and 21), KRAS (exon 12-13) and BRAF (V600E) in tissue samples (see laboratory accreditation nº750 / LE15156 Annex 7).
|
Open
|
Personalized oncology, Biotechnology, Diagnostic and molecular testing, Clinical trials, Molecular biology, Technology transfer, Pathology, Translational research, Liquid biopsy, In vitro drug testing, Dx platform validation, Drug development, R+D
|
Open
|
Sabino Arana 5-19
|
Barcelona
|
Barcelona
|
ES
|
08028
|
|
Pangaea Biotech
|
|
Health Care Equipment & Services
|
|
private:pangaeabiotech-2
|
1301518
|
Nov 7th, 2017 12:00AM
|
Pangaea Oncology
|
440
|
23.00
|
Open
|
Hospital & Health Care
|
Nov 7th, 2017 06:51PM
|
Nov 7th, 2017 06:51PM
|
Pangaea Oncology S.A provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Our research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Founded in 2007, we have grown rapidly to become a reference laboratory in our field and and have established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies.
Our mission is to generate a new framework of therapeutic oncology based on personalized models, and incorporate this strategy into standard medical practice.
For patient care, we are the molecular diagnostics laboratory of choice for the Dr Rosell Oncology Institute (IOR), based in the Dexeus, Teknon, General de Catalunya and Sagrat Cor hospitals, Quirónsalud Group. We are also the reference laboratory for cancer testing for the Dexeus University Hospital, Barcelona. Through these partnerships we gain valuable insights which inform our R+D programs.
We were the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (nº750 / LE15156 Annex 7). The laboratory is also accredited for analysis of EGFR mutations (exon 19, 20 (T790M) and 21), KRAS (exon 12-13) and BRAF (V600E) in tissue samples (see laboratory accreditation nº750 / LE15156 Annex 7).
Our Chief Scientific Officer is international expert in translational cancer research Dr Rafael Rosell, and our Pathology Unit is led by renowned expert pathologist Dr Santiago Ramon y Cajal. Our CEO Javier Rivela has over 12 years experience in investment banking.
The Pangaea team is composed of prestigious clinical and research professionals, combining expertise in preclinical cancer research with extensive experience in biomarker discovery, drug development and diagnostic tools with special focus on liquid biopsy.
|
|
|
|
|
|
|
|
|
|
Pangaea Biotech
|
|
Health Care Equipment & Services
|
|
private:pangaeabiotech-2
|
1301518
|
Nov 1st, 2017 12:00AM
|
Pangaea Oncology
|
435
|
24.00
|
Open
|
Hospital & Health Care
|
Nov 1st, 2017 06:25AM
|
Nov 1st, 2017 06:25AM
|
Pangaea Oncology S.A provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Our research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Founded in 2007, we have grown rapidly to become a reference laboratory in our field and and have established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies.
Our mission is to generate a new framework of therapeutic oncology based on personalized models, and incorporate this strategy into standard medical practice.
For patient care, we are the molecular diagnostics laboratory of choice for the Dr Rosell Oncology Institute (IOR), based in the Dexeus, Teknon, General de Catalunya and Sagrat Cor hospitals, Quirónsalud Group. We are also the reference laboratory for cancer testing for the Dexeus University Hospital, Barcelona. Through these partnerships we gain valuable insights which inform our R+D programs.
We were the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (nº750 / LE15156 Annex 7). The laboratory is also accredited for analysis of EGFR mutations (exon 19, 20 (T790M) and 21), KRAS (exon 12-13) and BRAF (V600E) in tissue samples (see laboratory accreditation nº750 / LE15156 Annex 7).
Our Chief Scientific Officer is international expert in translational cancer research Dr Rafael Rosell, and our Pathology Unit is led by renowned expert pathologist Dr Santiago Ramon y Cajal. Our CEO Javier Rivela has over 12 years experience in investment banking.
The Pangaea team is composed of prestigious clinical and research professionals, combining expertise in preclinical cancer research with extensive experience in biomarker discovery, drug development and diagnostic tools with special focus on liquid biopsy.
|
|
|
|
|
|
|
|
|
|
Pangaea Biotech
|
|
Health Care Equipment & Services
|